Antibody-dependent enhancement (ADE) of dengue virus infection occurs when neutralizing antibodies at sub-neutralizing concentrations or non-neutralizing antibodies form complexes with the virus. These virus-antibody complexes can then attach to a Fc7 receptor-bearing cell, via the Fc portion of the immunoglobulin, resulting in an increased number of infected cells. ADE may be responsible in part for the most severe clinical manifestations of dengue virus infection which include haemorrhage and shock. Three classes of human Fcy receptors exist, FcTRI, FcTRII and FcTRIII. In this study, we examined the effects of neuraminidase on ADE of dengue virus infection mediated by the lowaffinity FcTRII. K562 cells, which express only FcTRII, treated with neuraminidase resulted in augmentation of ADE of dengue virus infection by human anti-dengue antibodies. This augmented ADE of infection could be blocked by anti-FcTRII monoclonal antibody IV.3.
Introduction
Dengue viruses belong to the family Flaviviridae, genus flavivirus, and exist as four distinct serotypes. Transmission of dengue virus to humans occurs via a mosquito vector. Secondary infection by a dengue virus of a different serotype may result in severe clinical manifestations, including haemorrhage and plasma leakage, the so-called dengue haemorrhagic fever/dengue shock syndrome (Halstead et al., 1970; Sangkawibha et al., 1984; Burke et al., 1988) . It is believed that these complications in part may be secondary effects of antibody-dependent enhancement (ADE) of infection which results in an increased number of infected monocytes (Halstead, 1988) . The phenomenon of ADE occurs when neutralizing antibodies at sub-neutralizing concentrations or non-neutralizing antibodies bind dengue virus (Henchal et al., 1985; Morens et aI., 1987) . These virus antibody complexes bind via the Fc portion of IgG to Fc7 receptor (Fc?R)-bearing cells resulting in enhancement of dengue virus infection (Halstead et al., 1977; Peiris et al., 1981) .
Human Fc7Rs are sialoglycoproteins that exist as three distinct classes. Human FcyRI has a high affinity for monomeric IgG and an M r of 72K (Anderson, 1982) . Both FcTRII and FcTRIII are low-affinity receptors of M r 40K and 50K to 80K, respectively (Rosenfeld et al., 1985; Van de Winkel & Anderson, 1991) . Fc7RII is the most widely distributed Fc7 R and can be detected on monocytes, macrophages, neutrophils, platelets, eosinophils and B cells (Unkeless, 1989) . We have shown that ADE occurs via Fc~RI and FcTRII by using mouse anti-dengue virus antibodies (Kontny et al., 1988; Littaua et al., 1990) . However, the affinity of human IgG for FcTRII is low even for antigen-antibody complexes (Tax & Van de Winkel, 1990 
Methods
Cell line. The human erythroleukaemia cell line K562 (Lozzio & Lozzio, 1975) was grown in RPMI 1640 medium (Gibco), supplemented with 10% fetal calf serum (FCS) (Gibco), penicillin (100 units/ml) and streptomycin (100 pg/ml).
Virus and titration of virus. Dengue 2 virus, New Guinea C strain, was supplied by Walter E. Brandt of the Walter Reed Army Institute of Research, Washington, D.C., U.S.A. The virus was propagated in mosquito cells (C6/36) as previously described (Kurane et al., 1984) . The titre of virus pools was 3-5 x 107 to 1.0 x 108 p.f.u, per ml as determined by a plaque titration assay on CV-1 cells. Virus samples were serially l:10 diluted with MEM/0.5 % FCS at 4 °C. CV-1 cell monolayers in 24-well plates were washed twice with MEM/0.5% FCS, then 0-1 ml of the serially diluted virus sample was placed on the CV-1 monolayer, and incubated at 37 °C for 2 h. The plates were rocked every 15 min. After incubation, the fluids were removed, the cells were washed once with MEM/0.5% FCS, and 1 ml overlay, prepared as stated below, was placed on the cells. The plates were then incubated at 37 °C for 7 days prior to plaque quantification.
Preparation of overlayer for virus titration.
A suspension of 2.3 % carboxymethylcellulose in H20 was prepared and autoclaved. For preparing 100 ml of overlay, 80.8 ml of 2.3 % carboxymethylcellulose, 10ml of 10xMEM, 4ml of 7.5% NaHCO~, lml of l% DEAE dextran, 0.6 ml of essential vitamins, 0.6 ml of non-essential amino acids, l ml of FCS, 1 ml of the mixture of 10000 units/ml penicillin and 10000 gg/ml streptomycin and 1 ml of 200mM-Lglutamine were mixed at room temperature.
Antibodies. IV. 3 is a murine IgG2b monoclonal antibody (MAb) to Fc?RII (Looney et al., 1986) , BBMI is a murine IgG2b MAb to [?2-microglobulin (Brodsky et al., 1979) , 2H2 is a dengue complex-specific mouse IgG2a MAb directed against the preM protein (Henchal et al., 1985) . IV. 3 was kindly provided by Medarex.
The bispecific antibody IV.3 x 2H2 was prepared as previously described (Mady et al., 1991) . Fab fragments of IV. 3 at 2 to 4 mg/ml were treated with a fourfold molar excess of the bifunctional reagent Nsuccinimidyl 3-(2-pyridyldithio) propionate (SPDP) (Pharmacia) at 18 °C for 2 h, and then dialysed in PBS, pH 7.4.2H2 Fab in 50 mMphosphate buffer, 5 mM-EDTA, pH 7.5 (phos/EDTA), was treated with a threefold molar excess of N-succinimidyl S-acetylthioacetate (SATA; Calbiochem-Behring Diagnostics), dissolved in dimethyl formamide at 18 °C for 30 rain. After dialysis in phos/EDTA, the SATA 2H2 was deacetylated by adding hydroxylamine to 0.05 N and 1 h incubation at 18 °C. Hydroxylamine was removed by passage through a 10 ml Sephadex G-25 column (Pharmacia). The SATA-2H2 was mixed at once with an equimolar amount of IV. 3 Fab, and incubated at 18 °C for 4 h, after which cross-linking was terminated with 1 m~-iodoacetamide. Bispecific antibodies were then dialysed into PBS and purified by HPLC gel filtration chromatography using a BioSil TSK-250 column (Bio-Rad). Coupling one antibody fragment to SPDP and the other to SATA, as described above, allowed the directed preparation of heteroconjugates while minimizing the amount of bomoconjugates formed. Unreacted monomers were removed by the HPLC purification step. The bispecificity of these preparations was ensured by testing binding to cells using indirect immunofluorescence and by testing binding to dengue virus by ELISA.
The serum from a donor immunized 2 years earlier with the dengue 3 virus strain CH53489 (Innis et al., 1988) was used as a source of antidengue virus antibody. The neutralizing titre of this serum was 1 : 16 for dengue 3 virus and < 1:4 for dengue 2 virus. This serum detected dengue 2 virus antigens by indirect immunofluorescence staining.
Treatment of cells" with neuraminidase. K562 cells were initially washed in neuraminidase buffer (10 mM-sodium phosphate buffer pH 6.1, 150 mM-NaC1, 5mM-CaCl2). Then 1 ml of neuraminidase (Clostridium perfringens, type V, Sigma) at various concentrations diluted in RPMI/10% FCS or medium alone was added to 2 x 106 cells, incubated at 37 °C for 30 min and the cells were washed twice with RPMI/10 % FCS.
Infection of cells" with dengue virus. Virus antibody complexes were prepared by incubating dengue virus and antibody at 4 °C for 1 h. After washing in RPMI/10% FCS, K562 cells were resuspended at 2 x 106 cells/ml. Cell suspension (0.05 ml) was added to 0.20 ml of dengue virus or to the dengue virus-antibody complexes and incubated for 1 h at 37 °C. The cells were infected at an mo.i. of 10 p.f.u./cell or as specified. Following infection, the cells were washed twice in RPMI/10% FCS and cultured in 1 ml of RPMI/10% FCS at 37 °C for 24 or 48 h. In the blocking experiments the K562 cells were first incubated with the blocking antibody at room temperature for 1 h and then infected as described above.
lmmunofluorescence. Following the 24 or 48 h incubation, the cells were stained for the presence of dengue viral antigens by indirect immunofluorescence as previously described (Littaua et al., 1990) . The first antibody was from a murine hyperimmune ascitic fluid raised against dengue 2 virus and the second antibody was a fluorescein isothiocyanate (FITC)-conjugated sheep anti-mouse IgG (Cappel Laboratories). The neuraminidase-treated and untreated K562 cells were stained with anti-FcyRII MAb IV.3 and then with a second antibody, FITC-conjugated sheep anti-mouse IgG. Fluorescence was determined with a Becton-Dickinson flow cytometer. Quantitative fluorescein microbeads (Flow Cytometry Standards) were used for calibration to convert the fluorescence intensity values obtained from the flow cytometer into the number of molecules of second antibody bound per cell.
Rosetting. K562 cells were washed with neuraminidase buffer and then incubated with RPMI/10% FCS or neuraminidase at 1.25 x 10 -a units/ml as described above. Human RBC were washed three times with RPMI and incubated with various concentrations of human RhD antibody (Cutter Biological) for 30 min at 37 °C. The RBC were then washed three times with RPMI and resuspended at a concentration of 1 x l0 s cells/ml. K562 ~:ells (0.1 ml, 106/ml) were combined with 0.1 ml of 1 x 108 RBC/ml, centrifuged at 4 °C at 1000 r.p.m, for 10 min, and then allowed to stand at 4 °C for 2 h. The cells were then gently pipetted and 250 or more K562 cells were counted. Observation of four or more RBC adherent to a K562 cell was interpreted as positive rosette formation.
Statistical analysis'. Differences between the percentage of dengue virus antigen-positive cells were examined by chi-square analysis. Differences yielding P values of ~< 0.05 were regarded as significant.
Results

Neuraminidase augments Fc~RlI-mediated ADE of dengue virus infection
K562 cells were used to determine the effect of neuraminidase on ADE of dengue virus infection via FcFRII, because they express only FcyRII and not FcyRI or FcFRIII (Littaua et al., 1990) (Table 1 ). The highest level of enhancement found by using this antibody was observed at a 1 : 200 dilution (data not presented). When the cells were pretreated with neuraminidase, the antibody enhanced virus infection (as determined by the percentage of dengue virus antigen-positive cells) to significantly higher levels than that seen with untreated cells (Table 1) .
In addition, the viral titres from the culture supernatant fluids of K562 cells treated with neuraminidase and infected with dengue virus-antibody complexes were higher than in the supernatants of cells not treated with the enzyme but similarly infected (Table 1) . Treatment of cells with neuraminidase did not augment infection by dengue virus alone. Human serum from a dengue antibody-negative donor did not augment virus infection even when cells were pre-treated with neuraminidase (data not presented). These results demonstrated that neuraminidase augments FcFRII-mediated ADE of dengue virus infection.
MAb to FcFRH inhibits neuraminidase-induced augmentation of ADE
To confirm, that neuraminidase augments ADE via Fc~RII, neuraminidase-treated K562 cells were incubated with MAb to FcFRII and then infected with dengue virus-antibody complex. The mouse IgG2b MAb IV.3 directed against FcyRII inhibited the enhancement of infection mediated by anti-dengue antibody (Table 2) and had no significant effect on the infection of K562 cells by virus alone. In addition, the isotype control mouse IgG2b MAb BBMI did not inhibit infection of K562 cells with dengue virus or virusantibody complex. These results, along with the observation that neuraminidase does not augment infection in the absence of anti-dengue antibodies, indicate that augmentation of ADE by neuraminidase is mediated through FcyRII.
Neuraminidase augments FcyRII-mediated ADE by modulating the function and expression of the receptor
In order to evaluate the mechanisms by which neuraminidase augments ADE of infection, we examined whether enzyme treatment of K562 cells increased rosette formation via FcyRII using human RBC opsonized with human RhD antibody. The percentage of rosetteforming cells increased after neuraminidase treatment (data not presented). We then examined the effect of neuraminidase on ADE mediated by a bispecific antibody (IV. 3 × 2H2) which binds to both dengue virus and FcyRII. As previously reported, this antibody can mediate dengue virus ADE in K562 cells (Mady et al., 1991) . ADE mediated by the antibody was augmented in neuraminidase-treated K562 cells, but to a much lower degree than that seen using conventional anti-dengue IV. 3 x 2H2 47"9 ~ 38.3 ~ * K562 cells were pre-treated with neuraminidase (where indicated), washed and then infected with dengue virus or virus-antibody complex in which the antibody was human anti-dengue or bispecific IV. 3 x 2H2 (anti-FcyRII x anti-dengue virus).
? The percentages of dengue virus antigen-positive cells infected with virus-antibody complex with or without neuraminidase treatment were compared by chi-square analysis. ~P ~< 0.001. antibody (Table 3) . Neuraminidase augmented ADE using human anti-dengue virus antibody by 182 % in experiment 1 and 286% in experiment 2, and this augmentation was only 53 % in experiment 1 and 42 % in experiment 2 when the bispecific antibody was used.
To determine whether more antibody molecules bind to Fc?RII after neuraminidase treatment, enzymetreated K562 cells were stained with IV. 3 at various dilutions and then analysed with a fluorescence-activated cell sorter to quantify the number bound to the receptor. Quantitative fluorescein microbeads were used for calibration to convert the fluorescence intensity values obtained from the flow cytometer into the number of molecules of second antibody bound per cell. This number is a relative measure of the number of Fc?RII per cell. The number of molecules that bound to Fc):RII increased by 15 % and 20 % at antibody dilutions of 1 : 10 and 1 : 102, respectively, after neuraminidase treatment of K562 cells (Table 4) . At higher dilutions the number of IV. 3 molecules bound per cell approached the IgG2b control number. The discrepancy between the levels of augmentation of ADE by human anti-dengue virus antibody and those by the bispecific antibody, along with the low level of increase in the number of MAb IV. 3 molecules that bind to FcTRII after neuraminidase treatment suggest that this enzyme may act in a number of ways to augment ADE of dengue virus infection.
Discussion
The human IgG Fc receptors mediate a number of cellular functions including antibody-dependent cellmediated cytotoxicity, phagocytosis and superoxide generation (Van de Winkel & Anderson, 1991) . In addition, FcTRs may bind virus antibody complexes and enhance infection. This phenomenon is termed antibodydependent enhancement (ADE). ADE of dengue virus infection has been demonstrated to occur via FcyRI (Kontny et at., 1988) and FcyRII by using mouse antidengue antibodies (Littaua et al., 1990) . Interferon 7 upregulates FcTRI (Guyre et al., 1983; Perussia et al., 1983) and thereby augments ADE of dengue virus infection via this receptor (Kontny et al., 1988) . Although it is not known whether modulation of FcTRII leads to augmentation of ADE, it has been reported that the expression and affinity of FcTRII are modulated by cytokines and enzymes. Granulocyte and granulocytemacrophage colony-stimulating factors up-regulate FcTRII expression (Liesveld et al., 1988) . The proteases trypsin, pronase and elastase have been shown to increase its affinity without affecting the Mr, isoelectric focusing pattern or expression of this receptor (Van de Winkel et al., 1989) . In addition, neuraminidase also has been shown to modulate the function of FcTRII (Debets et aI., 1990) . Using human anti-dengue virus antibody and neuraminidase-treated K562 cells there was a significant augmentation of ADE of infection as determined by the percentage of dengue antigen-positive cells and viral titres. Similar results were also seen using murine antidengue virus antibody (data not presented). This ADE could be significantly blocked when the cells had been incubated with anti-Fc~RII MAb IV. 3 before infection by virus-antibody complexes.
There are a number of possible mechanisms by which neuraminidase may augment this ADE. Firstly, neuraminidase may act by affecting the as yet unidentified dengue virus receptor. At high enzyme concentrations (5 units/ml) there was a decrease in the number of infected cells when virus alone was used; however, dengue virus-antibody complexes were able to overcome this effect. At the concentration of neuraminidase (1.25 x 10 -a units/ml) used here, there was no effect on the infection of K562 cells with dengue virus alone. We conclude that the augmentation of ADE is secondary to the effects of neuraminidase on FcyRII itself. This conclusion is supported by the fact that in rosetting experiments using human RBC, human RhD antibody and K562 cells showed an increase in rosettes in neuraminidase-treated K562 cells compared to untreated cells, confirming the results of Debets et al. (1990) . In addition, the augmented ADE of infection could be blocked with anti-FcTRII MAb IV. 3.
Another possible mechanism of action of neuraminidase is that it increases the number of FcTRII molecules.
Quantitative fluorescence analysis demonstrated an increase in the amount of MAb IV. 3 binding to the receptor after neuraminidase treatment but the increase approached only 20% between neuraminidase-treated and untreated K562 cells. The augmentation of ADE using human anti-dengue antibody was 182 to 286% more in the neuraminidasetreated than in the untreated cells, and the augmentation of ADE using bispecific antibody was only slightly greater than 50%. Therefore, it is unlikely that the augmentation of ADE can be accounted for purely by an increased amount of FcyRII.
Neuraminidase may also increase the affinity of FcyRII. The bispecific antibody consists of a Fab portion of IV. 3 covalently linked to a Fab portion of 2H2 (antidengue virus MAb). If the augmentation of ADE with human anti-dengue virus antibody is exclusively mediated by an increase in the affinity of Fc~RII for the Fc portion of IgG, then one would not expect ADE by the bispecific antibody to be augmented after neuraminidase treatment. However, such ADE of infection was clearly augmented in neuraminidase-treated K562 cells, although to a lesser degree than that seen with whole human anti-dengue virus antibody.
Lastly, neuraminidase may increase the accessibility of Fc~RII. We speculate that neuraminidase cleaves sialic acid residues on FcTRII, allowing more efficient binding of both the Fc portion of IgG and the Fab of MAb IV. 3 to its epitope on FcTRII. In areas of inflammation various enzymes including proteases and neuraminidase have been reported to be present (LaMarco et aI., 1986; Tax & Van de Winkel, 1990) . It is possible that in vivo, during dengue virus infection, these enzymes modulate the function and expression of FcyRII allowing it to be active in ADE of infection, and to play an important role in the pathogenesis of dengue virus infection.
